NES-ZIONA, Israel, Sept. 13, 2011 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE Amex: PBTH), a clinical stage company developing next generation biobetter therapeutic proteins, today announced that company management will give a corporate presentation at the 2011 UBS Global Life Sciences Conference on September 20, 2011 at 9:30 AM EDT. The conference is being held at the Grand Hyatt Hotel in New York City.
A live webcast of the company's presentation will be available in the Investors section of PROLOR's website at www.prolor-biotech.com/?CategoryID=215. An archived version of the webcast will be available on the PROLOR website for 30 days beginning about three hours after the start of the presentation.
ABOUT PROLOR BIOTECH
PROLOR Biotech, Inc. is a clinical stage biopharmaceutical company applying unique technologies, including its patented CTP technology, primarily to develop longer-acting proprietary versions of already approved therapeutic proteins that currently generate billions of dollars in annual global sales. The CTP technology is applicable to virtually all proteins, and PROLOR is currently developing long-acting versions of human growth hormone, which is completing Phase II clinical development, as well as Factor VII, Factor IX, interferon beta, erythropoietin, an anti-obesity peptide and agents for atherosclerosis and rheumatoid arthritis, which are all in preclinical development. For more information, visit www.prolor-biotech.com.
SOURCE PROLOR Biotech, Inc.